Deaths (all conditions) · neuropathic pain (three studies in painful diabetic neuropathy)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Pain‐free at 2 hours · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Headache relief at 2 h · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Sustained pain‐free at 24 h · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Sustained headache relief at 24 h · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Number of participants reporting an adverse event · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Serious AE · migraine headache ‐ moderate or severe pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
At least 50% reduction in pain · patients with fibromyalgia
Pregabalin leads to higher 50% pain reduction compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · patients with fibromyalgia
Pregabalin leads to higher patient Global Impression of Change of 'much' or 'very much' improved compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Fatigue · patients with fibromyalgia
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia
1 finding from 1 review
Withdrawals due to adverse events · patients with fibromyalgia
Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Serious adverse events · patients with fibromyalgia
Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).
1 finding from 1 review
Dizziness · patients with fibromyalgia
Pregabalin leads to higher dizziness reported to be an adverse event compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Complete relief of pain · patients with metastatic bone pain
Radioisotopes probably leads to higher pain relief ‐ Complete relief compared with placebo (moderate certainty).
1 finding from 1 review
Pain relief ‐ Complete/Partial relief · patients with metastatic bone pain
Radioisotopes probably leads to higher pain relief ‐ Complete/Partial relief compared with placebo (moderate certainty).
1 finding from 1 review
Compression of spinal cord · patients with metastatic bone pain
Radioisotopes showed no clear difference in compression of spinal cord compared with placebo (low certainty).
1 finding from 1 review
Pain flares · patients with metastatic bone pain
Radioisotopes showed no clear difference in pain flares compared with placebo (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · patients with metastatic bone pain
Radioisotopes showed no clear difference in thrombocytopenia III‐IV compared with placebo (low certainty).
1 finding from 1 review
Leucocytopenia III‐IV · patients with metastatic bone pain
Radioisotopes may leads to higher leucocytopenia III‐IV compared with placebo (low certainty).
1 finding from 1 review